Elsevier

Progress in Cardiovascular Diseases

Volume 52, Issue 4, January–February 2010, Pages 347-361
Progress in Cardiovascular Diseases

Amyloid Heart Disease

https://doi.org/10.1016/j.pcad.2009.11.007Get rights and content

Abstract

The systemic amyloidoses are an uncommon group of disorders characterized by the extracellular deposition of amyloid in one or more organs. Cardiac deposition, leading to an infiltrative/restrictive cardiomyopathy, is a common feature of amyloidosis. It may be the presenting feature of the disease or may be discovered while investigating a patient presenting with non-cardiac amyloidosis. In this article we review the features of cardiac amyloidosis and its varied manifestations. The need for a high index of suspicion and the critical importance of precise biochemical typing of the amyloid deposits is stressed in light of recent advances in therapy which can, when appropriately used, significantly improve prognosis.

Section snippets

Amyloid heart disease: general overview

Amyloidosis most commonly involves more than one organ system. When a diagnosis of extracardiac amyloidosis has already been made, symptoms arising from the heart are readily attributable to cardiac amyloidosis. Unfortunately, when cardiac amyloidosis is an isolated disorder, or even when the cardiac manifestations of undiagnosed multiorgan amyloidosis predominate, the diagnosis is often not entertained until late in the course of the disease. The various types of systemic amyloidoses tend to

Clinical findings

The common clinical feature among the various forms of cardiac amyloidosis is the presence of congestive heart failure associated with a nondilated left ventricle with thickened walls and a normal or mildly reduced left ventricular ejection fraction. Because the disease affects all parts of the heart, biventricular heart failure is usually present, although the presenting feature is often that of severe right-sided heart failure. Peripheral edema may be profound and ascites is often present in

Echocardiography

Echocardiography is almost universally available and is usually one of the earliest tests employed in the investigation of suspected heart disease. Cardiac amyloidosis can be suspected by its typical appearance on the echocardiogram (Fig 5). The disease is characterized by ventricular wall thickening, due to amyloid infiltration of the myocardium, in the absence of left ventricular dilation. Unfortunately, even advanced cases of amyloidosis are sometimes misdiagnosed by cardiologists who are

AL amyloidosis

AL amyloidosis is probably the most commonly recognized form of amyloid heart disease. The disease is a plasma cell dyscrasia, in which circulating amyloidogenic light chains interact in the heart with cell membrane constituents and glycosaminoglycosides and other local matrix components.34 Deposition of amyloid occurs in the extracellular space, causing myocardial damage, and it has been postulated that there is also direct cell toxicity mediated by the formation of light chain oligomers.34

Treatment of AL cardiac amyloidosis

The approach to management of AL cardiac amyloidosis is twofold: treatment of the heart failure and treatment of the underlying plasma cell dyscrasia. Patients with AL amyloidosis of the heart tend to respond poorly to conventional heart failure therapies. Careful titration of diuretics and salt restriction remains the mainstay of management. Calcium-channel blockers have no role in the management and their use is often associated with significant worsening of heart failure.50 Despite the

Hereditary amyloidosis

Hereditary forms of cardiac amyloidosis are usually associated with mutation in the gene for the plasma protein transthyretin (TTR), and are referred to as ATTR. About 100 different amyloidogenic missense point mutations have been described80 and the heart is a frequent target for deposition in ATTR amyloidosis. The male to female ratio is around 50:50, in contrast to a slight male preponderance in AL amyloid with cardiac involvement.15 The amyloid deposits are composed of a combination of

Senile systemic amyloid

Wild-type TTR amyloid deposition (SSA) is found at autopsy in about 25% of individuals older than 80 years,81 although in most cases, the deposits are generally found in small quantities and there is no clinical significance or abnormality during life. The clinical picture of SSA occurs only when the amyloid deposits are extensive enough to produce an increase in left ventricular wall thickness. There is some evidence that, in SSA, the TTR is more likely to be composed of fragments of the TTR

Potential new therapies

Elucidation of aspects of the molecular pathogenesis of amyloid and amyloidosis is generating a variety of novel approaches to therapy.115, 116, 117, 118 Small molecule ligands that stabilize the native tetrameric structure of TTR and prevent its fibrillogenesis are being actively investigated for prophylaxis and therapy in TTR amyloidosis.119, 120, 121, 122, 123 The non steroidal anti-inflammatory diflusinal has been found to stabilize the tetrameric structure of TTR. This action reduces

Secondary (AA) amyloidosis

AA amyloidosis, previously termed secondary amyloidosis, is a rare complication of chronic inflammatory disorders. The fibrils are derived from the acute phase reactant SAA. Although cardiac deposits are often present on histology, echocardiographic abnormalities and clinical symptoms of cardiac AA amyloidosis are rare, occurring in only about 2% of cases. The prognosis is thought to be substantially better than in cases of AL amyloid.129 Treatment involves suppressing the underlying disease.

Isolated atrial amyloid

Atrial natriuretic peptide (ANP) is synthesized locally by atrial myocytes,130 and can be deposited locally within the atria as amyloid. Isolated atrial amyloid (IAA) is a disease of the elderly, with a female preponderance that contrasts with senile TTR amyloid.93 The incidence of IAA in elderly hearts is high, with one autopsy study describing IAA in 91 of 100 hearts.131 Isolated atrial amyloid first appears in the fourth decade, and its prevalence increases by approximately 15% to 20% per

Summary

Early detection of cardiac amyloidosis is the best method to obtain the best possible outcome, as it allows for a broader range of therapeutic options. Clinical awareness of the disease and a high index of clinical suspicion are critical to early diagnosis, but unfortunately, many cases are diagnosed late in the disease. In AL amyloidosis, severe cardiac involvement precludes high dose chemotherapy, but in the uncommon cases where infiltration is limited to the heart, combined heart

Statement of Conflict of Interest

The authors declare that there are no conflicts of interest.

References (137)

  • GertzM.A. et al.

    Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy

    Am J Cardiol

    (1997)
  • ArbustiniE. et al.

    Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients

    Am Heart J

    (1995)
  • PalladiniG. et al.

    Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL

    Blood

    (2006)
  • NordlingerM. et al.

    Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?

    Am J Cardiol

    (2005)
  • TakemuraG. et al.

    Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis

    J Am Coll Cardiol

    (1998)
  • DispenzieriA. et al.

    Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

    Blood

    (2004)
  • MurtaghB. et al.

    Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement

    Am J Cardiol

    (2005)
  • DinwoodeyD.L. et al.

    Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy

    Am J Cardiol

    (2008)
  • PollakA. et al.

    Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis

    Chest

    (1993)
  • HongoM. et al.

    Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings

    Am J Cardiol

    (2000)
  • KristenA.V. et al.

    Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death

    Heart Rhythm

    (2008)
  • ComenzoR.L. et al.

    Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients

    Blood

    (1998)
  • DubreyS. et al.

    Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival

    Am J Cardiol

    (1995)
  • DubreyS. et al.

    Cardiac transplantation for amyloid heart disease: The United Kingdom experience

    J Heart Lung Transplant

    (2004)
  • KpodonuJ. et al.

    Outcome of heart transplantation in patients with amyloid cardiomyopathy

    J Heart Lung Transplant

    (2005)
  • GillmoreJ.D. et al.

    Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

    Blood

    (2006)
  • ChenJ.M. et al.

    Alternate waiting list strategies for heart transplantation maximize donor organ utilization

    Ann Thorac Surg

    (2005)
  • MignotA. et al.

    Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients

    Arch Cardiovasc Dis

    (2008)
  • HessE.P. et al.

    Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients

    Resuscitation

    (2004)
  • YazakiM. et al.

    Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin

    Biochem Biophys Res Commun

    (2000)
  • ConnorsL.H. et al.

    Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis

    Am Heart J

    (2009)
  • ErikssonM. et al.

    Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene

    J Mol Diagn

    (2009)
  • KiuruS. et al.

    Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF)

    J Neurol Sci

    (1994)
  • HolmgrenG. et al.

    Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis

    Lancet

    (1993)
  • YazakiM. et al.

    Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients

    Am J Transplant

    (2007)
  • WestermarkP. et al.

    A primer of amyloid nomenclature

    Amyloid

    (2007)
  • ShirahamaT. et al.

    High-resolution electron microscopic analysis of the amyloid fibril

    J Cell Biol

    (1967)
  • WestermarkP.

    Aspects on human amyloid forms and their fibril polypeptides

    FEBS J

    (2005)
  • PellikkaP.A. et al.

    Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement

    Arch Intern Med

    (1988)
  • DubreyS. et al.

    Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation

    Br Heart J

    (1995)
  • FengD. et al.

    Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis

    Circulation

    (2009)
  • FengD. et al.

    Intracardiac thrombosis and embolism in patients with cardiac amyloidosis

    Circulation

    (2007)
  • ZubkovA.Y. et al.

    Primary systemic amyloidosis with ischemic stroke as a presenting complication

    Neurology

    (2007)
  • KoyamaJ. et al.

    Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis

    Circulation

    (2003)
  • DubreyS.W. et al.

    The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

    QJM

    (1998)
  • KwongR.Y. et al.

    Cardiovascular magnetic resonance in cardiac amyloidosis

    Circulation

    (2005)
  • SparrowP. et al.

    Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis

    J Magn Reson Imaging

    (2009)
  • MigrinoR.Q. et al.

    Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up

    BMC Med Phys

    (2009)
  • HoschW. et al.

    Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings

    Amyloid

    (2008)
  • MaceiraA.M. et al.

    Cardiovascular magnetic resonance in cardiac amyloidosis

    Circulation

    (2005)
  • Cited by (174)

    View all citing articles on Scopus

    Statement of Conflict of Interest: see page 358.

    View full text